Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFASHORT: High Dose Rifampicin for Pulmonary TB
NCT02581527Phase 3Completed
- Sponsor
- St George's, University of London
- Start
- Feb 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by St George's, University of London. Started Feb 2017; status: completed.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02581527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581527.